UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 190

Sortiert nach

Future prospects in biologic therapy for systemic lupus erythematosus

Nature reviews. Rheumatology, 2013-12, Vol.9 (12), p.705

Stohl, William

2013

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and Safety of Subcutaneous Belimumab in Systemic Lupus Erythematosus: A Fifty‐Two–Week Randomized, Double‐Blind, Placebo‐Controlled Study

Arthritis & rheumatology (Hoboken, N.J.), 2017-05, Vol.69 (5), p.1016-1027

2017

Link zum Volltext

Verfügbarkeit prüfen

Cytokine disturbances in systemic lupus erythematosus

Arthritis research & therapy, 2011-01, Vol.13 (4), p.228-228

2011

Link zum Volltext

Verfügbarkeit prüfen

Belimumab and Rituximab in Systemic Lupus Erythematosus: A Tale of Two B Cell-Targeting Agents

Frontiers in medicine, 2020-06, Vol.7, p.303-303

2020

Link zum Volltext

Verfügbarkeit prüfen

Industry Payments to United States Rheumatologist‐Authors of Publications in High‐Impact Rheumatology Journals

ACR open rheumatology, 2023-11, Vol.5 (11), p.609-618

2023

Link zum Volltext

Verfügbarkeit prüfen

The Future of B-cell Activating Factor Antagonists in the Treatment of Systemic Lupus Erythematosus

대한류마티스학회지, 2017, 24(2), , pp.65-73

Stohl, William

2017

Link zum Volltext

Verfügbarkeit prüfen

Inhibition of B cell activating factor (BAFF) in the management of systemic lupus erythematosus (SLE)

Expert review of clinical immunology, 2017-06, Vol.13 (6), p.623-633

Stohl, William

2017

Link zum Volltext

Verfügbarkeit prüfen

Therapeutic targeting of the BAFF/APRIL axis in systemic lupus erythematosus

Expert opinion on therapeutic targets, 2014-04, Vol.18 (4), p.473-489

Stohl, William

2014

Link zum Volltext

Verfügbarkeit prüfen

Innate and adaptive immune cell interaction drives inflammasome activation and hepatocyte apoptosis in murine liver injury from immune checkpoint inhibitors

Cell death & disease, 2024-02, Vol.15 (2), p.140-140

2024

Link zum Volltext

Verfügbarkeit prüfen

Deficiency of Type I IFN Receptor in Lupus-Prone New Zealand Mixed 2328 Mice Decreases Dendritic Cell Numbers and Activation and Protects from Disease

The Journal of immunology (1950), 2009-11, Vol.183 (9), p.6021-6029

2009

Link zum Volltext

Verfügbarkeit prüfen

Reductions in circulating B cell subsets and immunoglobulin G levels with long-term belimumab treatment in patients with SLE

Lupus science & medicine, 2022-02, Vol.9 (1), p.e000499

2022

Link zum Volltext

Verfügbarkeit prüfen

Promotion of T Regulatory Cells in Mice by B Cells and BAFF

The Journal of immunology (1950), 2020-05, Vol.204 (9), p.2416-2428

2020

Link zum Volltext

Verfügbarkeit prüfen

Belimumab for the treatment of pediatric patients with lupus nephritis

Expert opinion on biological therapy, 2023-03, Vol.23 (3), p.243-251

2023

Link zum Volltext

Verfügbarkeit prüfen

Urinary TWEAK as a biomarker of lupus nephritis: a multicenter cohort study

Arthritis research & therapy, 2009-01, Vol.11 (5), p.R143-R143

2009

Link zum Volltext

Verfügbarkeit prüfen

BAFF promotes Th17 cells and aggravates experimental autoimmune encephalomyelitis

PloS one, 2011-08, Vol.6 (8), p.e23629-e23629

2011

Link zum Volltext

Verfügbarkeit prüfen

Accelerated Pathological and Clinical Nephritis in Systemic Lupus Erythematosus-Prone New Zealand Mixed 2328 Mice Doubly Deficient in TNF Receptor 1 and TNF Receptor 2 via a Th17-Associated Pathway

The Journal of immunology (1950), 2009-02, Vol.182 (4), p.2532-2541

2009

Link zum Volltext

Verfügbarkeit prüfen

Novel evidence‐based systemic lupus erythematosus responder index

Arthritis and rheumatism, 2009-09, Vol.61 (9), p.1143-1151

2009

Link zum Volltext

Verfügbarkeit prüfen

Differential Development of Systemic Lupus Erythematosus in NZM 2328 Mice Deficient in Discrete Pairs of BAFF Receptors

Arthritis & rheumatology (Hoboken, N.J.), 2015-09, Vol.67 (9), p.2523-2535

2015

Link zum Volltext

Verfügbarkeit prüfen

Editorial: The BAFFling Immunology of Systemic Lupus Erythematosus: Beyond B Cells

Arthritis & rheumatology (Hoboken, N.J.), 2015-03, Vol.67 (3), p.612-615

Stohl, William

2015

Link zum Volltext

Verfügbarkeit prüfen

Therapeutic targeting of B lymphocyte stimulator (BLyS) in the rheumatic diseases

Endocrine, metabolic & immune disorders drug targets, 2006-12, Vol.6 (4), p.351

Stohl, William

2006

Link zum Volltext

Verfügbarkeit prüfen

Maternal and cord blood BAFF and APRIL levels during pregnancy

American journal of reproductive immunology (1989), 2023-03, Vol.89 (3), p.e13654-n/a

2023

Link zum Volltext

Verfügbarkeit prüfen

Inhibition of B cell activation following in vivo co-engagement of B cell antigen receptor and Fcγ receptor IIb in non-autoimmune-prone and SLE-prone mice

Journal of translational autoimmunity (Online), 2021-01, Vol.4, p.100075-100075, Article 100075

2021

Link zum Volltext

Verfügbarkeit prüfen

B Cell and T Cell Dissimilarities in BAFF-Deficient versus BR3-Deficient C57BL/6 Mice

The Journal of immunology (1950), 2022-12, Vol.209 (11), p.2133-2140

2022

Link zum Volltext

Verfügbarkeit prüfen

Paucity of Clinical Disease despite Serological Autoimmunity and Kidney Pathology in Lupus-Prone New Zealand Mixed 2328 Mice Deficient in BAFF

Journal of Immunology, 2006-08, Vol.177 (4), p.2671-2680

2006

Link zum Volltext

Verfügbarkeit prüfen

Biologic Differences Between Various Inhibitors of the BLyS/BAFF Pathway: Should We Expect Differences Between Belimumab and Other Inhibitors in Development?

Current rheumatology reports, 2012-08, Vol.14 (4), p.303-309

Stohl, William

2012

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 190

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(145)
Mit Volltextzugriff
(170)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(130)
Life Sciences & Biomedicine
(127)
Humans
(105)
Animals
(60)
Female
(60)
Immunology
(59)
Rheumatology
(56)
Male
(48)
Mice
(47)
Biological And Medical Sciences
(44)
Lupus Erythematosus, Systemic - Immunology
(42)
B-Lymphocytes - Immunology
(38)
Adult
(35)
Medical Sciences
(32)
Middle Aged
(32)
Lupus Erythematosus, Systemic - Drug Therapy
(23)
Systemic Lupus Erythematosus
(23)
Lupus
(22)
Treatment Outcome
(22)
T-Lymphocytes - Immunology
(21)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Future prospects in biologic therapy for systemic lupus erythematosus

Efficacy and Safety of Subcutaneous Belimumab in Systemic Lupus Erythematosus: A Fifty‐Two–Week Randomized, Double‐Blind, Placebo‐Controlled Study

Cytokine disturbances in systemic lupus erythematosus

Belimumab and Rituximab in Systemic Lupus Erythematosus: A Tale of Two B Cell-Targeting Agents

Industry Payments to United States Rheumatologist‐Authors of Publications in High‐Impact Rheumatology Journals

The Future of B-cell Activating Factor Antagonists in the Treatment of Systemic Lupus Erythematosus

Inhibition of B cell activating factor (BAFF) in the management of systemic lupus erythematosus (SLE)

Therapeutic targeting of the BAFF/APRIL axis in systemic lupus erythematosus

Innate and adaptive immune cell interaction drives inflammasome activation and hepatocyte apoptosis in murine liver injury from immune checkpoint inhibitors

Deficiency of Type I IFN Receptor in Lupus-Prone New Zealand Mixed 2328 Mice Decreases Dendritic Cell Numbers and Activation and Protects from Disease

Reductions in circulating B cell subsets and immunoglobulin G levels with long-term belimumab treatment in patients with SLE

Promotion of T Regulatory Cells in Mice by B Cells and BAFF

Belimumab for the treatment of pediatric patients with lupus nephritis

Urinary TWEAK as a biomarker of lupus nephritis: a multicenter cohort study

BAFF promotes Th17 cells and aggravates experimental autoimmune encephalomyelitis

Accelerated Pathological and Clinical Nephritis in Systemic Lupus Erythematosus-Prone New Zealand Mixed 2328 Mice Doubly Deficient in TNF Receptor 1 and TNF Receptor 2 via a Th17-Associated Pathway

Novel evidence‐based systemic lupus erythematosus responder index

Differential Development of Systemic Lupus Erythematosus in NZM 2328 Mice Deficient in Discrete Pairs of BAFF Receptors

Editorial: The BAFFling Immunology of Systemic Lupus Erythematosus: Beyond B Cells

Therapeutic targeting of B lymphocyte stimulator (BLyS) in the rheumatic diseases

Maternal and cord blood BAFF and APRIL levels during pregnancy

Inhibition of B cell activation following in vivo co-engagement of B cell antigen receptor and Fcγ receptor IIb in non-autoimmune-prone and SLE-prone mice

B Cell and T Cell Dissimilarities in BAFF-Deficient versus BR3-Deficient C57BL/6 Mice

Paucity of Clinical Disease despite Serological Autoimmunity and Kidney Pathology in Lupus-Prone New Zealand Mixed 2328 Mice Deficient in BAFF

Biologic Differences Between Various Inhibitors of the BLyS/BAFF Pathway: Should We Expect Differences Between Belimumab and Other Inhibitors in Development?

Suchergebnisse filtern